title: Valuable lessons from treatment of non-small cell lung cancer with erlotinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor.
authors.affiliation: Beatson West of Scotland Cancer Centre, Clinical Oncology, Gartnavel General Hospital, Glasgow, G12 0YN, UK. dr_shrimali@hotmail.com
authors.forename: Raj K
authors.initials: RK
authors.lastname: Shrimali
authors.forename: Peter D
authors.initials: PD
authors.lastname: Correa
authors.forename: Mohammed
authors.initials: M
authors.lastname: Rizwanullah
mesh_terms: D000328:Adult; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000556:secondary; D003875:Drug Eruptions / Q000188:drug therapy / Q000209:etiology; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D000069347:Erlotinib Hydrochloride; D017809:Fatal Outcome; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D047428:Protein Kinase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D011799:Quinazolines / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D000069347:Erlotinib Hydrochloride; D066246:ErbB Receptors